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Background: An intervention was designed to introduce rapid diagnostics tests for malaria (mRDTs) into registered
drug shops in Uganda to encourage rational and appropriate treatment of malaria with artemisinin-based combination
therapy (ACT). We conducted participatory training of drug shop vendors and implemented supporting interventions
to orientate local communities (patients) and the public sector (health facility staff and district officials) to the behavioral
changes in diagnosis, treatment and referral being introduced in drug shops. The intervention was designed to
be evaluated through a cluster randomized trial. In this paper, we present detailed design, implementation and
evaluation experiences in order to help inform future studies of a complex nature.
Methods: Three preparatory studies (formative, baseline and willingness-to-pay) were conducted to explore perceptions
on diagnosis and treatment of malaria at drug shops, and affordable prices for mRDTs and ACTs in order to inform the
design of the intervention and implementation modalities. The intervention required careful design with the intention to
be acceptable, sustainable and effective. Critical components of intervention were: community sensitization and creating
awareness, training of drug shop vendors to diagnose malaria with mRDTs, treat and refer customers to formal health
facilities, giving pre-referral rectal artesunate and improved record-keeping. The primary outcome was the proportion of
patients receiving appropriately-targeted treatment with ACT, evaluated against microscopy on a research blood slide.
Results: Introducing mRDTs in drug shops may seem simple, but our experience of intervention design, conduct and
evaluation showed this to be a complex process requiring multiple interventions and evaluation components drawing
from a combination of epidemiological, social science and health economics methodologies. The trial was conducted in
phases sequenced such that each benefited from the other.
Conclusions: The main challenges in designing this trial were maintaining a balance between a robust intervention to
support effective behaviour change and introducing practices that would be sustainable in a real-life situation in tropical
Africa; as well as achieving a detailed evaluation without inadvertently influencing prescribing behaviour.
Trial registration: NCT01194557 registered with ClinicalTrials.gov 2 September 2010.
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A key malaria control strategy in Sub-Saharan Africa is
to reduce malaria-related mortality and severe morbidity
through early diagnosis and effective case management
[1]. In up to 80% of malaria cases, care is provided outside
the formal health sector and polypharmacy is common
[2,3]. Shops selling anti-malarial drugs are numerous, easily
accessible, more oriented towards satisfying consumer
needs, less prone to drug stock-outs than government
health facilities and are therefore often visited as the
first source of treatment [2-5]. Strategies to ensure prompt
effective treatment with artemisinin-based combination
therapy (ACT) in Africa need to take into account the role
of drug shops in management of malaria and to ensure
that appropriate anti-malarial drugs are sold to pa-
tients [6].
The World Health Organization (WHO) recommends
that management of malaria should include confirmation,
either microscopically or with an antigen-based rapid
diagnostic test (mRDTs), of all suspected malaria cases
before treatment with relatively costly ACT [6]. Rapid
diagnostic tests to confirm malaria infection are reported
to be accurate, simple to use with minimal training and
potentially cost-effective in the context of ACT use [7-10].
However, experience has shown that while mRDTs are
relatively simple technologies, their introduction as a tool
for diagnosis is not straightforward [11-17]. With the ma-
jority of malaria cases being ‘self-diagnosed’ by the patient
and treated with drugs purchased from a local shop,
changes in diagnostic practice are not only needed
amongst public healthcare providers, but also amongst
patients themselves, pharmacies and drug shops. The
availability of diagnostic confirmation in drug shops may
increase willingness to pay for new ACT treatment since
customers would clearly know whether they have malaria
or not.
A study was conducted to examine the feasibility and
effectiveness of introducing mRDTs into registered drug
shops in Uganda to encourage rational and appropriate
treatment of malaria. Study outcomes were anti-malarial
drug prescription practices in drug shops, as well as ac-
ceptability and demand for improved diagnosis, purchase
of mRDTs and use of ACTs. The primary trial endpoint
was the proportion of patients receiving appropriately-
targeted treatment with ACT, evaluated against microscopy
on a research blood slide collected at the time of consult-
ation. The study also aimed to examine the economic con-
sequences of diagnostic testing for households, including
the cost of initial consultation and medicines purchased at
the drug shop, as well as any subsequent treatment-seeking
behaviour within the following 14 days. It was hypothesized
that the use of diagnostic testing would reduce over-
diagnosis and over-prescription of anti-malarial drugs in
the private sector. It was further hypothesized that theavailability of diagnostic confirmation of malaria would in-
crease uptake and sale of ACT (rather than monotherapy
or cheaper, less efficacious, anti-malarial drug combi-
nations), and would also encourage purchase of the full
treatment dose, as well as patient adherence to the full
course of ACT.
This paper reports the design, implementation and
methods of evaluation of the intervention study and
summarizes it under seven themes, namely: i) the study
setting, ii) characteristics of the recipients, iii) the con-
tent of the intervention, iv) characteristics of those de-
livering the intervention, v) the mode of delivery, vi)
the intensity and duration, and vii) methods to evaluate
adherence to intervention (fidelity to treatment protocols)
as previously recommended [18,19]. Specific considerations
when undertaking an intervention trial in the context of
drug shops in Sub-Saharan Africa are discussed.
Methods
The study setting
The study was conducted in Mukono District in central
Uganda. Like most of Uganda, the district is endemic for
malaria and the majority of the population (88%) live in
rural areas. The total population of the district is 850,900
with an annual growth rate of 2.3% and predominantly con-
sists of subsistence farmers of the Baganda ethnic group.
The policy in Uganda supports public-private partnerships
to improve health outcomes and registered drug shops are
thus supposed to participate in the prevention and treat-
ment of malaria [20].
To inform the design of the intervention, a series of
formative research studies were undertaken, including
focus group discussions (with community members,
health workers and drug shop vendors), a baseline sur-
vey of registered drug shops in the study area and exit
interviews with customers. In addition, a willingness-
to-pay survey was also conducted. The findings from
this formative research are published in full elsewhere
[21-24], but we highlight key findings pertinent to the
design of the intervention below.
Characteristics of the recipients (registered drug shops and
drug shop customers)
In Uganda, registered drug shops are licensed to sell non-
prescription drugs, including anti-malarial drugs but not
antibiotics or injections. They are expected to be operated
by a qualified health worker and fulfill minimum building
standards and are subject to periodic inspection by the
District Assistant Drug Inspector (DADI), with a license
renewable annually for a fee. A total of 59 registered drug
shops within 20 geographical clusters were eligible to par-
ticipate in the trial and were invited to attend a training
workshop, the characteristics of which were recorded in the
baseline survey [21,22]. Most were located in peri-urban
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prised of one to two rooms with one to two staff. On
the day of the baseline survey, the majority of drug
shop staff present were female, most had attained second-
ary level education, and approximately 50% were qualified
health workers (state enrolled nurse or above). Nonetheless,
few had previously received any specific training on the
management of malaria or use of mRDTs, and knowledge
on first-line treatment for malaria was low. All drug shops
reported being open at least five days a week, with the
majority (68%) open every day. Opening hours were long,
with many shops open up to 10 pm at night, consistent
with other findings that most trade occurs in the evening
[25]. Typically, drug shop vendors (DSVs) reported seeing
around 10 febrile patients each day (range 2 to 50 patients).
The formative research undertaken with community
members, drug shop vendors (DSVs) and health offi-
cials highlighted the need for the intervention design
to respond to the character of registered drug shops,
sometimes trusted and distrusted by the community,
and their dual role as both folk practitioners and pro-
viders of modern biomedicine [23].
Since the intervention aimed at improving the diagno-
sis of malaria and prescription practices of DSVs, these
were also recipients of the intervention. Their character-
istics have been described above. For the intervention to
be successful, patients had to be present at the drug
shops for the diagnostic testing to be performed. The
possibility that customers come to buy drugs for others
was an initial concern. The exit interviews were helpful
in confirming that in the majority of cases, the patient
came to the drug shop in person to seek treatment for a
fever, and that diagnostic testing was indeed feasible. Pa-
tients seeking treatment for fever at registered drug
shops ranged in age from 1 month to 76 years, with ap-
proximately a third being children under the age of
5 years and a further third being adults above 18 years.
These data were useful in understanding the treatment-
seeking patterns and consultation rates at drug shops.
This helped to design the patient follow-up procedure
and to estimate the number of patients who were likely
to receive an mRDT, ACT and/or pre-referral rectal arte-
sunate. Microscopic examination of blood samples taken
during the exit interview were used to determine the
proportion of febrile patients with malaria parasites
that purchased an ACT at baseline, as well as over-
prescription to parasite-negative patients, and to inform
sample size calculations for the primary endpoint of the
trial (appropriate ACT treatment). The qualitative re-
search revealed that mRDTs were not wholly unfamiliar
to community members, and importantly that there was
a pre-existing perception that not all fevers are malaria,
and that diagnostic testing was viewed as potentially
helpful in reducing this uncertainty [22,23]. However, thequalitative findings showed that there were concerns in
the community that mRDTs could test for HIV and that
the purchasing advice given by the DSV might be influ-
enced by a desire to get profit from drug sales. These
findings were used to identify key messages for informa-
tion leaflets that were used to raise awareness in the com-
munity of the purpose of malaria diagnostic testing and
its availability in government facilities and registered drug
shops.
The content of the intervention
The content of the intervention was based on findings
from the formative research of public health officials,
non-governmental organization (NGO) staff and re-
searchers and policymakers with previous experiences of
implementing interventions with DSVs in Uganda. This
helped to develop the underlying principles for the inter-
vention (Table 1, Figure 1) and to situate the interven-
tion in the context of other public health programs. The
intervention was designed to address key deficiencies
and challenges to appropriate diagnosis and treatment in
drug shops, such as the lack of training in national mal-
aria treatment guidelines, lack of reference materials
(guidelines, job aids), limited record-keeping in shops
and weak linkages with the public health system, which
had been identified during the formative research. The
intervention arm received training to cover the rationale
for diagnostic testing in febrile patients, performing an
mRDT and interpretation of the test result, while drug
shop vendors (DSVs) in the control arm were trained in
presumptive diagnosis of malaria.
Development of a training manual, job aids and standard
operating procedures
The trainer’s manual and accompanying job aids were
designed by the research team to highlight the import-
ance of appropriate treatment of malaria with ACT as
the first line anti-malarial drug in accordance with the
Ministry of Health (MOH) malaria management guide-
lines. Additional job aids were developed by the team,
including for a treatment algorithm, and summary guid-
ance on detecting danger signs and referring patients.
Training and job aids focused on recognizing the signs
of severe malaria and administration of rectal artesunate
as a pre-referral treatment, followed by referral to a
health facility for specialized care. It was also recognized
that in some circumstances there might be need to refer
patients who had other symptoms and/or were mRDT-
negative to a health facility, and guidelines were provided
on when to consider referral. However, in recognition that
many DSVs were qualified health workers with varied levels
of training and experience, these guidelines were not
intended to be prescriptive, allowing drug shop vendors
with the knowledge and means to provide other non-
Table 1 Components and content of the intervention in the mRDT and control arms
Intervention
component
Intervention (mRDT) arm Control arm
Training of
DSVs
Four-day interactive training workshops covering practical skills,
knowledge and communication skills in the following topics:
Three-day interactive training workshops covering practical skills,
knowledge and communication skills in the following topics:
• The new role of DSVs with ACT and mRDT • The new role of DSVs with Coartem
• How to receive clients, confirm fever and start recording • How to receive clients, assess fever and start recording
• Performing and reading an mRDT and blood slides • How recognize and assess clients with signs of severe illness
• How to recognize clients with signs of severe illness • Taking a blood slide
• How to treat clients who are mRDT-positive, including
treatment of uncomplicated malaria with Coartem and
treatment and referral of severe malaria including rectal
artesunate suppositories
• How to treat clients with fever
• How to deal with clients who are mRDT-negative, including
referral and explaining negative mRDT results
• How to check for any other signs of illness
• Keeping records, storage and monitoring mRDT and ACT • Keeping records, storage and monitoring of Coartem
Job aids Take-home materials: flow chart, job aid incorporating mRDTs,
artesunate and referral forms; Danger r signs
Take-home training manual; flow chart job aid incorporating
presumptive treatment, artesunate and referral; referral job aid for
presumptive treatment; danger signs job aid for presumptive
treatment
Referral forms Supply of referral forms for sending with clients to health facilities,
colour-coded for routine or emergency referral, incorporating
mRDT results
Supply of referral forms for sending with clients to health facilities,
colour-coded for routine or emergency referral
Certification A4 certificate detailing completion of course in ‘Use of
Artemisinin-based combination therapies and Rapid diagnostics
tests for home-based management of fever in Uganda’ with
Ministry of Health logo
A4 certificate detailing completion of course in ‘Use of
Artemisinin-based combination therapies for home-based
management of fever in Uganda’ with Ministry of Health logo
Supportive
supervision
Initial 3-month period of intense support with regular weekly
visits conducted by project staff with on-the-spot feedback on
Coartem and mRDT use, record-keeping and other project-
related topics
Initial 3-month period of intense support with regular weekly
visits conducted by project staff with on-the-spot feedback on
Coartem use, record-keeping and other project- related topics
Registers and
stock cards
Supply of registers with treatment record forms for each client
including mRDT recording; supply of stock cards to monitor
supply of Coartem (yellow and blue), mRDTs, rectal artesunate
and blood slides
Supply of registers with treatment record forms for each client;
supply of stock cards to monitor supply of Coartem (yellow and
blue), rectal artesunate and blood slides
Supplies Distribution of mRDTs and Coartem by the study team either
by direct delivery or visits from DSVs to the project office.
Continuous supply was ensured through visits and mobile
phone communication between DSVs and project staff.
Distribution of Coartem by the study team either by direct
delivery or visits from DSVs to the project office. Continuous
supply was ensured through visits and mobile phone
communication between DSVs and project staff.
Recommended
retail pricing
Pricing lists for mRDTs and Coartem provided to DSVs with
Ministry of Health logo
Pricing lists for Coartem provided to DSVs with Ministry of Health
logo
Advertising
placard
Each DSV was given a placard to place in the roadside near
their shop to advertise the availability of malaria diagnostics.
No placards were given.
Community
sensitization
Meetings within 8 sub-counties (in which the 20 clusters were located) to meet political leaders and get their consent; training
of sub-county trainers, identifying Village Health Teams (VHTs) who would carry out community sensitization; and to organize
training of VHTs.
SOPs Distribution and training in standard operating procedures for project activities including completion of records, making blood
slides, storage of project-related materials, logistics of supplies and collections for blood slides
Supplies of
project
materials
Supply of materials for carrying out blood slides for the trial evaluation, including gloves, lancets, slides and storage, sharps boxes.
Routine collection of blood slides and sharps boxes, ensuring supply of materials required.
Health facility Sensitization about project
Health units in the study area were visited and made aware of the referrals from DSVs and requested to keep records on the referrals.
Legend:
mRDT Rapid Diagnostic Test for malaria.
DSV Drug Shop Vendor.
ACT Artemisinin-based Combination Therapy.
VHT Village Health Teams.
Coartem Artemisinin/lumefantrine.
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Figure 1 Logical model to explain elements of the intervention.
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vant to patient safety, including safe disposal of sharps and
bio-waste, storage conditions and expiration dates. In
addition to the job aids, drug shop vendors were provided
with treatment registers, referral forms, and stock cards to
support good practice in stock management. Simple record
forms were designed so as to not be too time consuming to
complete, and to respect the privacy of DSV business trans-
actions. All forms were translated into the local language,
which included the referral form, with the hope that this
would help patients understand why they were being re-
ferred, and was considered a facilitatory factor for accept-
ability and uptake of referral advice by patients.
The training manual was based on a curriculum that
enabled theory and practice, encouraging interactive dis-
cussion and reflective practice, supported by practical
exercises and role-plays. The pictorial job aids and re-
cording forms were distributed and used by DSVs during
these exercises. Role plays were devised to practice the
communication skills necessary to obtain a relevant clin-
ical history, to explain the outcome of the mRDT test,
reason for treatment given, and where appropriate, refer-
ral advice. Two versions of the manual and report forms
were produced for each arm of the trial, which differed
only in the method of malaria diagnosis to be used (con-
trol treatment based on signs and symptoms only or
mRDT-based). In all other respects, the content of the
intervention and the training were identical in order thatthe attribution of effect could be based on the use of
mRDTs rather than the accompanying training, materials
and activities.
The intensity of the intervention (supporting
interventions)
The intervention also aimed at addressing challenges
that drug shops were expected to face in implementing
diagnostic testing, for example recognizing that DSVs
would need to broker this change with communities.
Thus in addition to the technical skills to improve
diagnosis and treatment, DSVs were also trained in ne-
gotiation and communication skills. The design of the
training manual was based on adult learning principles,
intending to be interactive and participatory. Supporting
interventions were also undertaken to enhance commu-
nity acceptability of mRDTs through the provision of
leaflets to village health teams summarizing key mes-
sages and community sensitization to change. At the
end of the training, DSVs were presented with a certifi-
cate with the MOH logo in the presence of the District
Health Team and local community leaders to confirm
their new status as a trained malaria treatment provider.
Drug shops in the mRDT arm were also given a placard
to place at the roadside advertising the availability of
malaria diagnostic tests at their premises. The training,
certification and community sensitization activities were
also intended to legitimize the role of registered drug
Table 2 Some issues raised by drug shop vendors during
supervision
Some issues raised by drug shop vendors during supervision
• What will the drug shop vendors do when the study ends?
• Due to poverty, there are some people who still want to buy less
tablets of ACT and they end up taking an under-dose
• Some caretakers leave patients at home and come to buy anti-malarial
drugs, hence it can be difficult to get blood for testing
• Some patients fear to be pricked for the blood sample
• Some patients/caretakers asked for the results of the research slide
(control arm)
• Some patients with danger signs do not comply when referred
because they do not receive adequate care at health units
• The referral forms are ignored and despised by the staff at health
facilities because they are written in Luganda (local language)
• After hearing about mRDT some people also came for other
tests like HIV, typhoid and syphilis.
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ment, and so minimize distrust and skepticism towards
DSVs by the community and other health providers.
The mode of delivery of the intervention
Community sensitization
Prior to implementation, a meeting was held with the
District Health Team (DHT) to share objectives and the
scope of the study. This was followed by meetings within
eight sub-counties (in which the 20 clusters were located)
to meet political leaders and obtain their agreement for
the trial to be undertaken in their locality. Community
sensitization was undertaken through a process of cascade
training using existing district health structures. Sub-
county trainers were orientated on the aims and objectives
of implementing RDT in registered drug shops and proce-
dures to be introduced. The specific roles of the trainers
were to identify Village Health Teams (VHTs) who would
carry out community sensitization, organize a one-day
training of VHTs and supervise the subsequent community
sensitization. The VHTs were trained before the start of the
trial to inform communities within the study area about the
study, its purpose and what to expect. The information
given to participants during community sensitization activ-
ities was summarized in the information leaflet for VHTs
and translated into the local language (Luganda). Both the
sub-county trainers and the research team supervised
VHTs on a weekly basis. Health units in the study area were
visited and made aware of the intervention in drug shops,
the possibility of referrals from DSVs and requested to keep
records on patients referred.
Randomization and DSV training
There is an increased risk of randomization failure in
cluster randomized trials with a small number of clusters,
with an increased possibility that study arms are unbal-
anced with respect to potential confounders, undermining
the credibility of trial findings. To counter this risk, and to
balance cluster-related factors that might a priori be asso-
ciated with the primary outcome or expected to influence
the effect of the intervention between the two study arms,
restricted randomization informed by the baseline survey
was used to allocate eligible drug shop clusters to the
intervention. A total of 20 clusters were randomized to
the control or the intervention arm (10 per arm). All reg-
istered drug shops located in eligible clusters were invited
to attend a training workshop in malaria diagnosis and
treatment, and informed written consent was obtained
from drug shop owners who attended the training, agree-
ing to participate in the trial and its evaluation. Training
workshops for drug shop vendors (DSVs) in the interven-
tion arm lasted four days, to include topics relating to
mRDTs specifically. In the control arm, DSVs were invited
to a three-day workshop with the same content andinteractive style but without training on mRDTs. The
training was modular (see Table 1 for topics) and was con-
ducted by a team composed of the District Health Educa-
tor (DHE), the Principal Investigator from the Ministry of
Health and the Field Coordinator.
Adherence to the study protocols (supervision)
After commissioning the intervention, for an initial period
of two months immediately after training DSVs were pro-
vided with additional close support supervision (in both
arms) to assist with the adoption of the new diagnosis and
treatment procedures into their everyday practice with
intervention arm, and record- keeping and quality of blood
slides in the control arm. This comprised weekly site visits
conducted by project staff to support DSVs to implement
the intervention and also to encourage accurate and
complete record-keeping. A supervisory checklist was used
and issues and questions raised were recorded (Table 2.
The DSVs were given on-the-spot feedback and a date for
next supervision agreed on. Intense support supervision
ended at the end of December 2010, with a reduction in
the number and frequency of site visits (Table 3). In this
way, we sought to provide the additional support required
to achieve behaviour change whilst recognizing the finan-
cial and logistic constraints to supervision under realistic
programmatic conditions with limited funding.
Pricing and stock management
The trial was designed to uphold the principle enshrined
in the Affordable Medicines Facility for Malaria (AMFm)
that to assure access to effective malaria treatment,
ACTs need to be affordable for the majority of the popu-
lation. During the trial, DSVs were therefore provided
the mRDTs and ACT treatments free of charge, and ex-
pected to sell these at a low cost to their customers. Rec-
ommended retail prices for mRDTs and ACT were
Table 3 Supply management of mRDT and drugs
Supply management of mRDT and drugs
• Procure mRDT and drugs
• Quality assurance of drugs and mRDT (arrange lot testing and
design and implement system for field testing of mRDT)
• Detailed plan for supply management (how requests are made,
frequency and who supplies)
• Monitoring and action on leakage of drugs and mRDT
Table 4 The study timelines
Study activity Time period
Formative research May - July 2010
Baseline survey June - August 2010
Randomization September 2010
Training October - November 2010
Intense supervision November - December 2010
Evaluation phase January - December 2011
Household surveys September 2011 - June 2012
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site-specific willingness-to-pay study [24]. The recom-
mended retail prices for mRDTs and ACT were agreed
with DSVs at the time of training, but were not adver-
tised to the community, as we wished to monitor price
adherence. However, later on, drug shops did request
that they be given an official recommended retail price
list to show to customers at time of purchase.
Logistics and stock management
DSVs were supplied with an initial stock of mRDTs and
ACT, but thereafter were expected to collect their supplies
from a project office established at Mukono town, as re-
quired. This was considered realistic since DSVs would
come to town periodically to replenish other drug stocks.
The project office was staffed with a dedicated project offi-
cer to provide support and supervision to the DSVs, keep
stock of drugs, mRDTs and other supplies, and coordinate
data management of completed treatment forms and
research blood slides on a daily basis, as well as a mi-
croscopist and two data clerks. During the formative re-
search, baseline and final evaluation surveys, four to
five experienced social scientists were recruited and
trained to conduct the focus group discussions, client
exit interviews and household interviews. A vehicle and
driver were provided to enable drug shop visits during
the phase of close support supervision and later evalu-
ation surveys. Key logistical issues in supply manage-
ment are listed in Table 3.
Evaluating the impact of the intervention
Evaluation of the outcomes
Evaluation of the intervention to assess the primary and
secondary endpoints was undertaken towards the end of
the first year of implementation (Table 4). This allowed
practices to normalize before evaluation and to prevent re-
search activities influencing provider behaviour (Table 5).
The primary outcome of the intervention was the pro-
portion of patients receiving appropriately-targeted
treatment with ACT, defined as an ACT provided to
malaria blood side parasite-positive patients. In the
mRDT arm, blood was taken from consenting patients
to perform both an mRDT and a thick blood film. In
the control arm only a thick blood film was taken. Theblood films were transported to the Vector Control
Division of the Ministry of Health in Kampala and ex-
amined by a laboratory technician. The small number
of febrile patients typically seen each day meant that
patient exit interviews during the baseline survey proved
costly and time consuming. In addition, the majority of cus-
tomers are often seen in the evening, introducing practical
constraints and risks of sampling bias. These constraints,
coupled with the concern that exit interviews might also in-
fluence provider behaviour through increasing compliance
with the treatment guidelines during the period of obser-
vation (Hawthorne effect [25]), influenced our choice of
evaluation methods during the trial. Likewise, we did not
attempt to directly observe consultations. We therefore
evaluated provider behaviour (adherence to test result,
treatment given, referral) primarily through the establish-
ment of a routine reporting system. DSVs were provided
with carbon-copy treatment and referral registers: one
copy was retained by the DSV, one submitted to the pro-
ject office, and in the case of referrals, one copy was also
given to the client. We felt it was realistic to expect private
providers participating in a program with subsidized com-
modities to contribute data to a health management infor-
mation system (HMIS), and that routine reporting could
also support accountability and stock management. The
impact of the intervention was thus evaluated on the basis
of the mRDT result and anti-malarial treatment recorded
in patient treatment records routinely completed by DSVs
on patients seen during a full 12-month period after the
end of the close support supervision. This was in order to
capture the full range in seasonal variation in consultation
and mRDT positivity rates, under conditions of routine
implementation (with very limited supervision and exter-
nal influence). Nonetheless, the evaluation of treatments
given was based on self-reported data, and could be vul-
nerable to selective and/or inaccurate reporting by DSVs.
In order to assess this, a number of other methods were
used to provide corroborative data to assess the validity of
the reports, including the collection and re-reading of
mRDTs to assess the inter-rater reliability of interpretation
and recording of mRDT results by DSVs. Studies in the
private sector often use simulated client visits, in which
Table 5 Outcomes, sources of data and type of analyses
Endpoint Source of data Planned analyses
Primary endpoints: Appropriate treatment Treatment record form The proportion of patients receiving appropriate treatment
will be calculated as follows: (number of patients who are
slide-positive and were given a 1st-line anti-malarial + the
number of patients who are slide-negative and not given a
1st-line anti-malarial) divided by total febrile consultations.
Over-prescription Treatment record form
Accessibility to ACT and mRDTs
Proportion of patients who are not parasite-positive (slide-negative),
who receive inappropriate ACT treatment from a drug shop, with the
proportion of incorrectly treated malaria cases being based on the
‘gold standard’ of a research blood slide.
Provider adherence with mRDT result Treatment record form Proportion of patients who receive appropriate ACT treatment,
consistent with mRDT result. Depending on the severity of
symptoms an mRDT-positive patient is expected to have received
either artemether-lumefantrine (Coartem) tablets or a rectal
artesunate suppository.
Cost-effectiveness Treatment record form,
Implementation costs,
Incremental societal cost per additional case of appropriate
treatment resulting from introducing mRDT in drug shops:
Day 14 household visits Incremental costs of the mRDT intervention will be calculated by
subtracting the societal costs in the current practice arm from the
societal costs in the mRDT arm. The incremental effect will be
measured as the difference in the number of cases receiving
appropriate treatment (primary endpoint) in the current practice
arm and the mRDT arm.
Secondary endpoints: Prompt appropriate
treatment
Treatment record form Proportion of patients seen at a registered drug shop who receive
appropriate ACT treatment within 24 hours of onset of malaria
symptoms
Referral: appropriate management of mRDT-
negative patients
Treatment record form Appropriate treatment of mRDT-negative patients (lack of anti-malarial
sale and provision of referral.
Referral: timeliness and uptake of referral by
patients
Referral forms, referral follow-up
visits
Timeliness and uptake of referral at a health unit by referred
patients. The mean time interval between referral and uptake
for patients taking up the severe referral will be compared
between arms
Patient adherence to ACT Day 4 patient follow-up visit, Proportion of patients followed up on day 4 that were prescribed
ACT and took the full 3 day dose in the correct manner.
Adherence to treatment is based on examination of the blister
pack, if available, and the patient/caregivers report of how the
treatment was taken during day 4 patient follow-up interview.
Equity of diagnosis Day 14 household visits Proportion of patients with fever receiving a diagnostic test for
malaria, compared across socio-economic groups. Denominator:
Households with at least one person with a history of fever
within the last 14 days.
Equity of treatment Day 14 household visits Proportion of patients with malaria (slide-positive), receiving
treatment with an ACT, compared across socio-economic groups.
Denominator: Households with at least one person with a history
of fever within the last 14 days.
Acceptability of mRDT to patients Treatment record form (refusals),
Day 4 patient follow-up visit,
Focus group discussions
Proportion of patients with fever accepting to purchase a
diagnostic test; proportion of ACT sales preceded by a
positive test.
Perceptions of ACT, mRDTs and acceptability
of the intervention (community, drug shops
health staff)
Focus group discussions Data from focus group discussions and key informant interviews
will be transcribed and transferred to NVivo version 8 (QSR
International); a software program for the management and
analysis of qualitative data. Coding of the transcripts will
take place through an iterative process. Initially data will be
grouped into themes drawn from idea codes to generate a
‘node tree of ideas’.
Legend:
mRDT Rapid Diagnostic Test for malaria.
DSV Drug Shop Vendor.
ACT Artemisinin-based Combination Therapy.
NVivo qualitative data analysis software; QSR International Pty Ltd. Version 8, 2008.
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ing quality of service, compliance with regulation or gath-
ering specific information about products and services
[26]. The use of stimulated client visits was not feasible as
a means of evaluating the main outcome of our study,
since this required a sample of blood to be collected from
the client. Nevertheless, a small number of simulated cli-
ent visits were conducted to assess adherence to treatment
guidelines in specific situations where a patient might de-
cline a blood test or the patient is not present for testing.
Towards the end of the first year of implementation,
interviews were also conducted with a random sample of
500 patients at their place of residence 10 to 14 days
after the initial drug shop consultation. In addition to
providing an independent confirmation of the treatment
received, price adherence by DSVs and elicitation of
patient views on the acceptability of the diagnosis and
services at drug shops, this follow-up also aimed to cap-
ture the full costs of treatment borne by the household
(through inclusion of costs incurred both at the time of
initial consultation and further treatment-seeking under-
taken in the subsequent two weeks, no later than 14 days
after the initial consultation minimize recall bias). Patient
follow-up interviews also provided data on patient adher-
ence to the full three-day course of ACT treatment and
active surveillance for adverse events. To obtain a random
sample, field assistants approached DSVs according to a
randomized schedule and obtained a list of all patients
who were treated with ACT in the previous four days and
thus eligible for follow-up. Tracing patients proved labori-
ous, with interviewees in paid employment and in peri-
urban areas more likely to be absent at the time of the
home visit. To mitigate risk of loss to follow-up and po-
tential bias, repeat visits were attempted and telephone
contacts and addresses of households were recorded rou-
tinely by the DSVs during the evaluation phase and used
to make appointments for follow-up by research assistants.
Evaluating the cost-effectiveness of the intervention
A cost-effectiveness component was designed with the
aim of comparing the cost per correctly treated fever pa-
tient in the intervention and the control arm. Data on
costs as well as effectiveness measured as correctly treated
patients (using microscopy as gold standard) by study arm
were captured. Unit costs of malaria treatment in public
health centers were also captured in order to incorporate
patients seeking additional care in public health centers
after visiting a drug shop. Recurrent and capital costs
borne by the health service for sensitizing the community,
training DSVs, supervising DSVs, purchasing and distrib-
uting ACT and mRDTs and other supplies required for
delivering the intervention were estimated. Evaluation of
the cost-effectiveness component was undertaken from a
societal perspective and costs included: a) those related todeployment of the intervention and borne by the health
service, and b) those incurred by the household when
seeking treatment for fever, including the direct costs of
transport, diagnosis and drugs and opportunity costs of
lost time and production.
Ethics
Ethical approval for the trial was granted from review
boards at the Uganda National Council of Science and
Technology (reference: HS 546) and the London School
of Hygiene and Tropical Medicine. At the time of elicit-
ing informed consent to participate in the trial, DSVs
were informed that mystery drug shop visits might take
place. Written informed consent was from drug shops
sought prior to all interviews.
Results and discussion
Coordination of a multi-disciplinary research team
The main challenge in designing this trial was its complex
nature that necessitated a combination of epidemiological,
clinical, social science and health economics methodologies.
We assembled a team of researchers with diverse skills as
this trial required strong team work, good collaboration
and harmonized decision-making.
Balancing robust interventions with real-life situations
Another challenge was maintaining a balance between a
robust intervention and introducing practices that would
be sustainable in a real-life situation for example, intro-
ducing records for DSVs aimed at evaluating the inter-
vention. However, we were mindful of the work load put
on staff and privacy attached to the customers, price levels
and the variety of drugs stocked. Similarly, the supervision
of DSVs was done with care not to be misunderstood as
inspection and control. To maintain a constant supply of
mRDTs and ACT at drug shops, DSVs would visit the pro-
ject office to bring treatment forms and pick up supplies
whenever they came to town to do other errands. This
provided a periodic opportunity for DSVs to raise any
challenges and resolve these individually with the project
supervisor on an ongoing basis. Mobile phones were also
used for communication with the project supervisor for
replenishing stocks and to solve field problems.
Sustainability and future scale-up of the intervention
The intervention was designed with a view to keeping
implementation and supervision costs to a minimum,
conforming to approaches typically used by the Ministry of
Health, such as utilizing networks of community health vol-
unteers for community sensitization and cascade training.
Close support supervision was limited to an initial period
of two months. To address potential issues of sustainability
during the scale-up of the intervention, we involved the
DHT members and community leaders from the inception
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amongst influential stakeholders. The DHE and the district
nursing officer participated in the early visits to the study
areas to meet with community leaders and select sub-
county trainers. The DHE was also involved in designing
training materials, pre-testing them and the training of
DSVs. Similarly, the DADI participated in the verification of
registered DSVs and reviewing training materials, especially
the referral forms.
Monitoring for contamination
In this trial we could not restrict patient choice in where
they chose to seek treatment, and the implications of
treatment-seeking by patients needed to be considered
when interpreting study findings. To minimize mixing
(crossover) of patient populations, a cluster randomized de-
sign was used, such that drug shops in close geographical
proximity were randomized to the same arm. Nevertheless,
since factors other than geographical proximity may influ-
ence which private provider a patient chooses to frequent,
we cannot assume that all patients resident in the same
parish visited the same cluster of drug shops. Polypharmacy
is the norm in many parts of Sub-Saharan Africa, and it is
also possible that during the course of treatment-seeking
one patient may visit more than one source of treatment.
Typically, almost half of patients had first sought treatment
elsewhere, and this could have included seeking treatment
from registered drug shops in clusters in a different arm, or
from other drug outlets not participating in the trial. There-
fore it was important to collect data on the village and
parish of residence to examine geographical patterns in
treatment-seeking and to monitor for crossover. By
examining where patients chose to go for treatment,
we were also able to directly monitor the acceptability
of the intervention to patients. Data on prior and subse-
quent treatment-seeking was collected in a sub-sample of
customers from both arms to allow monitoring of this
issue. Data was also collected on whether any staff at the
drug shop worked elsewhere, and if so, where and how
often.
Dropout of DSVs
Since high costs were noted to be a constraint to pa-
tients in the study area and likely to affect appropriate
treatment of febrile and non-febrile illnesses, meetings
were held with DSVs to discuss affordable prices for
ACT and mRDTs. This discussion was guided by a study
on willingness-to-pay for an mRDT and a course of
ACT [24]. Four drug shops in the intervention arm and
two in the control arm dropped out before training be-
cause they thought the intervention would not work and
therefore did not attend the training. This led to one
cluster in the mRDTs arm to drop out and the sample
size was recalculated. Later in 2011, two DSVs in theintervention arm dropped out. One shop closed down
and the other changed ownership and the new worker
did not wish to participate in the study. In the control
arm seven dropped out due to closure of business and
shifting to other locations. Drug shops differed in the
size of their client base, reflecting differences in location
and popularity. This was included as a balance criterion
in the restricted randomization, but differing levels of
patient recruitment (cluster size) also needed to be con-
sidered in analysis. The typically small number of staff
meant that some shops closed down temporarily during
periods of sickness or maternity leave, reducing sample size
in some clusters.
Monitoring provider behaviour
A key outcome of the study was to monitor whether
DSVs would adhere to the mRDT results and provide
appropriate treatment according to the guidelines. Con-
cerns had been voiced during the formative research
about the potential for profit motive to affect case man-
agement, especially adherence to the treatment guide-
lines to not sell an ACT in the face of negative mRDT
results. None of the evaluation methods were ideal, and
all carried some risk that DSVs might modify their be-
haviour in the knowledge that adherence to guidelines
was being monitored. To minimize this risk, we used
routine self-reported data, with additional validation data
collected using mystery shoppers and follow-up inter-
views with a sub-sample of patients timed to occur only
after the first full 12-monthsof implementation was
completed. Another concern was whether DSVs would
be motivated to refer customers into the public health
system, particularly given our formative research find-
ings of their difficult relationship with the formal system.
To address these issues a qualitative sub-study was de-
signed to document the treatment and referral of customers
by DSVs to formal health facilities through follow-up inter-
views with customers and focus group discussions with
DSVs, local health facility staff and patients who had been
referred.
Local initiatives by drug shops
In working with the commercial sector, the possibility
that some private providers might use the intervention
to promote their business which may inadvertently affect
the delivery of the intervention should not be over-
looked. For example, we found that in addition to the
initial community sensitization undertaken as part of the
planned intervention, some DSVs independently utilized
local radios to advertise the intervention, or advertised
their services in community meetings, church and women’s
groups. In some cases, DSVs also chose to advertise
the price of mRDTs and ACTs. This was considered an
innovation and we subsequently attempted to document
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this had on the success of patient recruitment, as part of
the process evaluation.Context of the intervention
The context in which a trial occurs needs also be consid-
ered. For example, treatment-seeking for malaria treatment
and acceptability of mRDT testing at drug shops are both
likely to be influenced by diagnostic and treatment prac-
tices in local health facilities, as well as by temporal fluctu-
ations in the availability of mRDTs and ACTs in the public
sector. From the baseline study, DSVs were not stocking
and using mRDTs [22]. To stabilize this effect on study
endpoints over the duration of trial, we found it was neces-
sary to periodically supplement government supplies of
mRDTs and ACTs to avoid stock-outs, which had major
cost implications for the study. To understand the broader
social context, we also undertook a discourse analysis to
examine how drug shops were usually portrayed in the na-
tional media and policy documents over the time period of
the study.
Within the trial itself, as part of the evaluation of this
complex intervention a number of contextual aspects
were investigated to situate the intervention within the
overall public health goal of increasing access to prompt
effective malaria treatment. In the study, epidemiological,
economic and socio-behavioral analyses were undertaken
to provide a comprehensive evaluation. The results of these
studies will help policymakers to make a decision on the
deployment of ACT and mRDTs in home-based manage-
ment of malaria in different settings. Research findings will
also help to identify how to achieve maximal coverage of
correct and appropriate malarial treatment and to minimize
misuse of ACT.Conclusions
This trial aimed to answer a ‘simple’ policy-relevant ques-
tion of whether mRDT should be introduced at drug
shops. The design of the intervention and the trial to
evaluate this was far from simple, and our account of
this here illustrates the network of people, materials, re-
sources, protocols and logistics that need to be coordi-
nated for such an intervention trial to be enacted.Abbreviations
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